vs
Apellis Pharmaceuticals, Inc.（APLS）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Resolute Holdings Management, Inc.的1.7倍（$199.9M vs $117.7M），Resolute Holdings Management, Inc.净利率更高（-1.5% vs -29.5%，领先28.0%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $-14.3M）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
APLS vs RHLD — 直观对比
营收规模更大
APLS
是对方的1.7倍
$117.7M
净利率更高
RHLD
高出28.0%
-29.5%
自由现金流更多
RHLD
多$203.5M
$-14.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $117.7M |
| 净利润 | $-59.0M | $-1.7M |
| 毛利率 | — | 55.7% |
| 营业利润率 | -25.6% | 30.2% |
| 净利率 | -29.5% | -1.5% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSRHLD
| Q4 25 | $199.9M | $117.7M | ||
| Q3 25 | $458.6M | $120.9M | ||
| Q2 25 | $178.5M | $119.6M | ||
| Q1 25 | $166.8M | $103.9M | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | — | ||
| Q1 24 | $172.3M | — |
净利润APLSRHLD
| Q4 25 | $-59.0M | $-1.7M | ||
| Q3 25 | $215.7M | $-231.0K | ||
| Q2 25 | $-42.2M | $-611.0K | ||
| Q1 25 | $-92.2M | $-3.4M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | — | ||
| Q1 24 | $-66.4M | — |
毛利率APLSRHLD
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 57.5% | ||
| Q1 25 | — | 52.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率APLSRHLD
| Q4 25 | -25.6% | 30.2% | ||
| Q3 25 | 48.7% | 34.3% | ||
| Q2 25 | -18.6% | 34.0% | ||
| Q1 25 | -50.0% | 24.7% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — | ||
| Q1 24 | -36.0% | — |
净利率APLSRHLD
| Q4 25 | -29.5% | -1.5% | ||
| Q3 25 | 47.0% | -0.2% | ||
| Q2 25 | -23.6% | -0.5% | ||
| Q1 25 | -55.3% | -3.2% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | — | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSRHLD
| Q4 25 | $-0.40 | $-0.20 | ||
| Q3 25 | $1.67 | $-0.03 | ||
| Q2 25 | $-0.33 | $-0.07 | ||
| Q1 25 | $-0.74 | $-0.39 | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $370.1M | $6.5M |
| 总资产 | $1.1B | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资APLSRHLD
| Q4 25 | $466.2M | $205.5M | ||
| Q3 25 | $479.2M | $148.0M | ||
| Q2 25 | $370.0M | $99.9M | ||
| Q1 25 | $358.4M | $71.0M | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSRHLD
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSRHLD
| Q4 25 | $370.1M | $6.5M | ||
| Q3 25 | $401.2M | $10.8M | ||
| Q2 25 | $156.3M | $9.6M | ||
| Q1 25 | $164.2M | $8.9M | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — | ||
| Q1 24 | $266.7M | — |
总资产APLSRHLD
| Q4 25 | $1.1B | $333.4M | ||
| Q3 25 | $1.1B | $293.2M | ||
| Q2 25 | $821.4M | $253.3M | ||
| Q1 25 | $807.3M | $214.3M | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — | ||
| Q1 24 | $831.9M | — |
负债/权益比APLSRHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $189.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 160.8% |
| 资本支出强度资本支出/营收 | 0.1% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $313.2M |
8季度趋势，按日历期对齐
经营现金流APLSRHLD
| Q4 25 | $-14.2M | $196.1M | ||
| Q3 25 | $108.5M | $59.6M | ||
| Q2 25 | $4.4M | $48.9M | ||
| Q1 25 | $-53.4M | $18.4M | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | — | ||
| Q1 24 | $-133.0M | — |
自由现金流APLSRHLD
| Q4 25 | $-14.3M | $189.2M | ||
| Q3 25 | $108.3M | $58.6M | ||
| Q2 25 | $4.4M | $47.5M | ||
| Q1 25 | $-53.4M | $17.8M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSRHLD
| Q4 25 | -7.1% | 160.8% | ||
| Q3 25 | 23.6% | 48.5% | ||
| Q2 25 | 2.5% | 39.7% | ||
| Q1 25 | -32.0% | 17.1% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSRHLD
| Q4 25 | 0.1% | 5.8% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSRHLD
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
RHLD
暂无分部数据
